Peptide-modified gene cassettes
The DNA-PepTAG workflow improves nuclear delivery of therapeutic genes by linking NLS peptides to DNA via triazole linkages, addressing inefficiencies in non-viral gene therapy and reducing DNA doses, enhancing nuclear localization and expression in non-dividing tissues.
Patent Information
- Application Number
- PCT/US2026/027172
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Efficient nuclear delivery of DNA in non-viral gene therapy remains a challenge due to limited effectiveness of nuclear localization signal (NLS) peptides in DNA-peptide conjugation strategies, with only ~1% of transfected DNA reaching the nucleus, necessitating high DNA doses that hinder biological and medical applications.
A modular workflow for generating DNA oligonucleotide-peptide conjugates, termed DNA-PepTAG, which involves linking NLS peptides to DNA via triazole linkages to enhance nuclear delivery through nuclear pore complexes, using methods like strain-promoted azide-alkyne cycloaddition to form peptide-modified gene cassettes.
Enhances nuclear delivery of therapeutic genes, minimizing required DNA doses and reducing cytotoxicity and immune activation, while avoiding risks associated with viral-based methods, particularly beneficial for non-dividing or slow-dividing tissues.
Smart Images

Figure US2026027172_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No. 15670-0461W01
[0002] PEPTIDE-MODIFIED GENE CASSETTES CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to U.S. Provisional Patent Application No.
[0004] 63 / 802,258 filed May 8, 2025, the contents of which are incorporated herein by reference in their entirety.
[0005] SEQUENCE LISTING
[0006] This application contains a Sequence Listing that has been submitted electronically as an XML file named “15670-0461 WO 1_SL_ST26. XML.” The XML file, created on May 6, 2026, is 28,652 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety.
[0007] BACKGROUND
[0008] Efficient nuclear delivery of DNA remains a major challenge in non-viral gene therapy. While nuclear localization signal (NLS) peptides have been explored to enhance nuclear translocation of exogenous DNA, their effectiveness has been limited by DNA-peptide conjugation strategies.
[0009] The effective delivery of exogenous DNA into cells is necessary for modern medical and technical advances including gene therapy, antisense oligonucleotides, and many genome editing applications via CRISPR-Cas9 and related systems. While viral methodologies for therapeutic DNA delivery have shown promise, significant safety concerns remain regarding immunogenicity, insertional mutagenesis, toxicity, and off target effects. Efficacy has also been limited due to restricted cargo capacity, scalability issues, and low targeting specificity. The success of mRNA based COVID-19 vaccines delivered through lipid nanoparticles (LNP) has motivated the application of non-viral delivery methods for DNA therapeutics. However, unlike mRNA which requires only entry into the cytosol, DNA therapeutics must be delivered to the nucleus. Non-viral techniques, including transfection of naked DNA, remain highly inefficient in this regard, and it is believed that only ~1% of DNA transfectedAttorney Docket No. 15670-0461W01
[0010] in mammalian cells is translocated to the nucleus, with a majority of DNA entering the nucleus through the breakdown and subsequent reformation of the nuclear envelope during cell division. Therefore, DNA gene therapy typically requires very high doses of DNA which has hindered biological and medical applications. Thus, there remains a need for compositions and efficient methods of nuclear delivery of DNA in non-viral gene therapy.
[0011] SUMMARY
[0012] Disclosed herein is a modular workflow for generating DNA oligonucleotide-peptide conjugates that are then ligated to linear DNA to generate peptide modified gene cassettes (DNA-PepTAG). Also disclosed herein are methods of delivering an exogenous nucleic acid to a nucleus of a cell. Also disclosed herein are compositions comprising a peptide-modified gene cassette, the peptide-modified gene cassette comprising: (i) an exogenous nucleic acid molecule; (ii) one or more linkers; and (iii) one or more nuclear localization (NLS) peptides. Also disclosed herein are methods of making a peptide-modified gene cassette. The compositions and methods disclosed herein can be useful as a viable strategy for non-viral gene therapy, enabling enhanced nuclear delivery of therapeutic genes while minimizing the required DNA dose.
[0013] In a first aspect, the disclosure provide methods of delivering an exogenous nucleic acid to a nucleus of a cell, the methods including: contacting the cell with a peptide-modified gene cassette, the peptide-modified gene cassette including: (i) an exogenous nucleic acid molecule; (ii) one or more linkers; and (iii) one or more nuclear localization (NLS) peptides; such that the peptide-modified gene cassette translocates through a nuclear pore complex of the nucleus of the cell, thereby delivering the exogenous nucleic acid to the nucleus of the cell.
[0014] In some embodiments, the exogenous nucleic acid molecule includes a DNA molecule. In some embodiments, the DNA molecule includes a gene of interest. In some embodiments, the gene of interest includes an open reading frame (ORF), one or more enhancers, one or more promoters, a poly-A tail, and one or more flanking restriction sites.
[0015] In some embodiments, the peptide-modified gene cassette further includes one or more stem loops. In some embodiments, the one or more NLS peptides are operably linked to the one or more stem loops. In some embodiments, the one or more NLS peptides are selected from the group consisting of Sv40, exSv40, Influenza A Virus A NP, IGFBP-2, Hrp-1, PLSCR-1, Borna Disease Virus plO (BVP), and HTLV-1 Rex. In some embodiments, theAttorney Docket No. 15670-0461W01
[0016] one or more linkers operably link each of the one or more stem loops to the one or more NLS peptides. In some embodiments, the one or more linkers is selected from the group consisting of (GGGGS)i (SEQ ID NO: 1), (GGGGS)2(SEQ ID NO: 2), (GGGGS)3(SEQ ID NO: 3), (GGGGS)4(SEQ ID NO: 4), and (GGGGS)s (SEQ ID NO: 5). In some embodiments, the peptide-modified gene cassette further comprises a triazole linkage. In some embodiments, the triazole linkage links the one or more stem loops to the one more linkers.
[0017] In another aspect, the disclosure provides compositions including a peptide-modified gene cassette, the peptide-modified gene cassette including: (i) an exogenous nucleic acid molecule; (ii) one or more linkers; and (iii) one or more nuclear localization (NLS) peptides. In some embodiments, the exogenous nucleic acid molecule is a DNA molecule. In some embodiments, the DNA molecule includes a gene of interest. In some embodiments, the gene of interest includes an open reading frame (ORF), one or more enhancers, one or more promoters, a poly-A tail, and one or more flanking restriction sites.
[0018] In some embodiments, the peptide-modified gene cassette further includes one or more stem loops. In some embodiments, the one or more NLS peptides are operably linked to the one or more stem loops.
[0019] In some embodiments, the one or more NLS peptides are selected from the group consisting of Sv40, exSv40, Influenza A Virus ANP, IGFBP-2, Hrp-1, PLSCR-1, Borna Disease Virus plO (BVP), and HTLV-1 Rex. In some embodiments, the one or more linkers operably link the each of the one or more stem loops to the one or more NLS peptides. In some embodiments, the one or more linkers is selected from the group consisting of (GGGGS)i (SEQ ID NO: 1), (GGGGS)2(SEQ ID NO: 2), (GGGGS)3(SEQ ID NO: 3), (GGGGS)4(SEQ ID NO: 4), and (GGGGS)s (SEQ ID NO: 5). In some embodiments, the peptide-modified gene cassette further comprises a triazole linkage. In some embodiments, the triazole linkage links the one or more stem loops to the one more linkers.
[0020] In another aspect, the disclosure provides methods of making a peptide-modified gene cassette, the methods including: contacting a preQl-DBCO with a DNA oligonucleotide stem loop to generate a DBCO modified DNA stem loop; forming a triazole linkage between the DBCO modified DNA step loop and an azido-peptide to generate a DNA oligonucleotidepeptide conjugate; contacting the DNA oligonucleotide-peptide conjugate with a gene cassette to generate a peptide-modified gene cassette.
[0021] In some embodiments, the methods further include extending the 5' end of the DBCO modified DNA step loop. In some embodiments, the methods further include extending the 3' end of the DBCO modified DNA step loop. In some embodiments, the extending forms aAttorney Docket No. 15670-0461W01
[0022] sticky end at the 5' end and / or the 3' end of the DBCO modified DNA step loop. In some embodiments, the gene cassette is a sticky-ended gene cassette. In some embodiments, the methods further include contacting the gene cassette to a second DNA oligonucleotidepeptide conjugate.
[0023] BRIEF DESCRIPTIONS OF THE DRAWINGS
[0024] FIG. 1 A shows a summary schematic of oDNA-NLS conjugates previously studied for nuclear translocation of a DNA cargo through the nuclear pore complex (NPC) presumably via NLS-nuclear transport protein interactions. DNA-NLS conjugates are summarized in three broad categories: NLS tagged nuclear proteins associated with DNA cargo, noncovalent interactions between DNA cargo and NLS peptides, and covalent interactions between DNA cargo and NLS peptide.
[0025] FIG. IB shows a schematic overview of NLS modified gene cassettes by DNA-PepTAG.
[0026] FIG. 2A shows a general workflow to generate DNA oligonucleotide-peptide conjugates. E. coli TGT irreversibly exchanges a specific guanine with a preQi-DBCO in a DNA oligonucleotide stem loop to generate a DBCO modified DNA stem loop. Strain-promoted azide-alkyne cycloaddition is leveraged to form a triazole linkage between the DBCO modified DNA stem loop and azido-peptide to generate a DNA oligonucleotidepeptide conjugate. The minimal TGT stem loop is highlighted in green with the target guanine in red. The stem loop can be extended at both the 5' and 3' ends; in this work the 5' end was extended to match the required restriction enzyme sticky end (i.e. Mlul).
[0027] FIG. 2B shows chemical structures of preQi probes and their modification of DNA stem loop by TGT activity. PreQi-biotin serves as a positive control for DNA-TAG activity. Urea-PAGE upwards gel shift observed between negative control (Mlul 170 PP DNA hairpin, lane 1) and preQi-biotin (lane 2) and preQi-DBCO (lane 3) with near quantitative yields.
[0028] FIG. 2C shows images of urea-PAGE upward gel shifts observed from the formation of various DNA oligo-peptide conjugates via strain-promoted azide-alkyne cycloaddition with near quantitative yields. Lane 1 - DBCO modified Mlul 170 PP DNA hairpin, Lane 2 -Sv40 KO Lx3, Lane 3 - Sv40 NLS LX3, Lane 4 - PLSCR-1 NLS Lx3, Lane 5 - exSv40 NLS Lx3.Attorney Docket No. 15670-0461W01
[0029] FIG. 2D shows a general scheme to generate peptide modified linear gene cassettes for mammalian cell expression. The gene of interest (including gene, enhancer, promoter, poly-A tail, and flanking restriction sites) is PCR amplified from plasmid DNA. The PCR product is then dual digested with relevant restriction enzymes (Mlul and Avril) to generate defined sticky ends on the PCR products. DNA stem loops designed with complimentary sticky ends may be modified with peptides (peptide A and / or B) and ligated to the sticky end gene fragment to generate a capped linear gene cassette.
[0030] FIG. 3 A shows optimization parameters of NLS modified eGFP gene cassettes. eGFP linear cassettes were transfected into aphidicolin growth arrested HepG2 cells and eGFP expression was monitored by microscopy and flow cytometry.
[0031] FIG. 3B shows representative epifluorescence microscopy images showing 48 h eGFP expression in growth arrested HepG2 cells transfected with linearized eGFP cassette, some modified with peptides. Scale bar: 50 pm.
[0032] FIG. 3C shows a plot of results of screening eGFP expression after 48 h in growth arrested HepG2 cells as flexible linker length (GGGGS)nis increased between DNA and the Sv40 NLS peptide. DNA was modified on the 5' Mlul side of the expression cassette (site A). Control is the unmodified linear eGFP cassette. Data were quantified using flow cytometry and are presented as mean ± s.d. for n = 5 biologically independent experiments, individual data points are overlaid, 100 ng DNA transfected per condition. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison (*p < 0.05,
[0033] **p < 0.01, ***p < 0.001, ****p < 0.0001, ns p>0.05).
[0034] FIG. 3D shows a plot of results of screening eGFP expression after 48 h in growth arrested HepG2 cells of NLS modified DNA cassette on the 5' Mlul (peptide A), 3' Avril
[0035] (peptide B), or both (peptides A and B). Control is the linear cassette modified on the 5' Mlul side with the Sv40 KO peptide, all peptides include the 3x linker ((GGGGS)s). Data were quantified using flow cytometry and are presented as mean ± s.d. for n = 5 biologically independent experiments, individual data points are overlaid, 100 ng DNA transfected per condition. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns p > 0.05).Attorney Docket No. 15670-0461W01
[0036] FIG. 3E shows a plot of results of 24 h eGFP expression with or without 10 |JM
[0037] importazole treatment in growth arrested HepG2 cells. Peptide modifications are on the 5' Mlul side of the gene cassette with the 3x linker ((GGGGS)3). Controls include eGFP plasmid, unmodified linear cassette, and the Sv40 KO modified cassette. Data were quantified using flow cytometry and are presented as mean ± s.d. for n = 5 biologically independent experiments, individual data points are overlaid, 100 ng DNA transfected per condition. Statistical analysis was performed using multiple unpaired t-tests (*p < 0.05, **p<0.01, ***p< 0.001, ****p< 0.0001, ns p>0.05).
[0038] FIG. 4A shows a table describing a suite of peptides selected for nuclear localization activity on a DNA cargo.
[0039] FIG. 4B shows plots of results of 48 h eGFP expression of peptide modified eGFP cassettes in growth arrested HepG2, HEK293T, and AC 16 cells. Data were quantified using flow cytometry and are presented as mean ± s.d. for n = 5 biologically independent experiments, individual data points are overlaid, 100 ng DNA transfected per condition. Controls include eGFP plasmid DNA, unmodified linearized eGFP cassette, and Sv40 KO modified eGFP cassette. All peptide modifications were on the 5' Mlul side of the cassette with the 3x linker ((GGGGS)3). Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns p>0.05).
[0040] FIG. 5A shows a plot of results of 48 h eGFP expression from titrated quantities of NLS modified eGFP cassettes in growth arrested HepG2 cells. Data were quantified using flow cytometry and are presented as mean ± s.d. for n = 5 biologically independent experiments, individual data points are overlaid.
[0041] FIG. 5B shows a plot of results of 48 h expression of differentially sized GFP DNA cargos modified with NLS peptides in growth arrested HepG2 cells. Data were quantified using flow cytometry and are presented as mean ± s.d. for n = 5 biologically independent experiments, individual data points are overlaid. Controls include the plasmid, unmodified linear cassette, and Sv40 KO modified cassette. All peptide modifications were on the 5' Mlul side of the cassette with the 3x linker ((GGGGS)3).
[0042] FIG. 5C shows a plot of results of 48 h factor IX expression of peptide modified factor IX cassettes secreted from growth arrested HepG2 cells. Controls included a negativeAttorney Docket No. 15670-0461W01
[0043] control, factor IX plasmid, unmodified linear cassette, and Sv40 KO modified cassette. Data were obtained by ELISA and presented as a mean ± s.d. for n = 4 biologically independent experiments, individual data points are overlaid, 100 ng DNA transfected per condition. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns p > 0.05).
[0044] FIG. 5D shows a plot of secretion of factor IX of NLS modified cassettes from growth arrested HepG2s cells over 120 h. Controls include a negative control, unmodified linear cassette, and Sv40 KO modified cassette. Data were obtained by ELISA and presented as a mean ± s.d. for n = 3 biologically independent experiments, 100 ng DNA transfected per condition.
[0045] FIG. 6 shows synthesis of preQi -DBCO with commercially purchased precursors FIG. 7 shows generation of DNA oligonucleotide - peptide conjugates via strain-promoted azide-alkyne click chemistry.
[0046] FIG. 8 shows exemplary images of urea-PAGE of DNA oligonucleotide - peptide conjugates.
[0047] FIG. 9 shows a plot of results of screening eGFP expression after 48 h in growth arrested HepG2 cells as flexible linker length (GGGG(S))nis increased between DNA and the Influenza NLS peptide. Data collected were quantified using flow cytometry and are presented as mean ± s.d. for n = 5 biologically independent experiments, individual data points are overlaid, 100 ng DNA transfected per condition. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison (*p < 0.05, **p < 0.01,
[0048] ***p < 0.001, ****p < 0.0001, ns p > 0.05).
[0049] DETAILED DESCRIPTION
[0050] Disclosed herein is a modular workflow for generating DNA oligonucleotide-peptide conjugates that are then ligated to linear DNA to generate peptide modified gene cassettes (method termed “DNA-PepTAG”). The modular platform disclosed here, DNA-PepTAG, can be used to generate site-specific peptide-modified gene cassettes. Also disclosed herein are methods of delivering an exogenous nucleic acid to a nucleus of a cell. Also disclosed herein are compositions comprising a peptide-modified gene cassette, the peptide-modified geneAttorney Docket No. 15670-0461W01
[0051] cassette comprising: (i) an exogenous nucleic acid molecule; (ii) one or more linkers; and (iii) one or more peptides, e.g., nuclear localization (NLS) peptides. Also disclosed herein are methods of making a peptide-modified gene cassette. The compositions and methods disclosed herein can be useful as a viable strategy for non-viral gene therapy, enabling enhanced nuclear delivery of therapeutic genes while minimizing the required DNA dose. The advantages of these methods of exogenous nucleic acid delivery include minimizing the required DNA dose which can reduce cytotoxicity and immune activation. The advantages also include avoiding the risks of viral-based gene therapy methods which can include genotoxicity, hepatotoxicity, thrombotic microangiopathy, and neurotoxicity. When the peptides of the peptide-modified gene cassettes are NLS peptides, gene cassettes modified with a single NLS peptide show significantly enhanced nuclear localization and expression in cells. These methods are particularly advantageous for therapeutic applications targeting nondividing or slow-dividing tissues, such as the liver, kidney, or muscle, where nuclear delivery is a major bottleneck for exogenous gene expression.
[0052] In various embodiments, of the disclosed methods, an exogenous nucleic acid molecule (e.g., a DNA gene cassette encoding a gene of interest) is modified with one or more nuclear localization sequence (NLS) peptides via one or more linkers, optionally through a triazole linkage, to facilitate translocation through a nuclear pore complex (NPC) and thereby enhance delivery of the exogenous nucleic acid into the nuclear compartment. The gene of interest can be, for example, a therapeutic gene intended to treat a disease state.
[0053] In some embodiments, the peptide-modified gene cassette includes one or more stem loop structures that serve as attachment loci and / or structural features that enable coupling of NLS peptides to the nucleic acid. In further embodiments, the peptide-modified gene cassette is generated by coupling an azido functionalized peptide to a DBCO-functionalized nucleic acid component to form a triazole linkage, and then associating (e.g., ligating, annealing, or otherwise assembling) the resulting nucleic acid peptide conjugate to a gene cassette encoding a gene of interest to generate the peptide-modified gene cassette.
[0054] The embodiments described herein are intended to be illustrative rather than limiting. Various modifications and variations will be apparent to those skilled in the art and are within the scope of the present disclosure.
[0055] As used herein, “peptide-modified gene cassette” refers to a gene cassette encoding one or more genes of interest that is covalently and / or non-covalently associated with one or more peptides directly or through one or more linkers and / or chemical linkages e.g., tri azole).Attorney Docket No. 15670-0461W01
[0056] Peptide-Modified Gene Cassettes
[0057] The peptide-modified gene cassettes disclosed herein have a general architecture including (i) an exogenous nucleic acid encoding a gene of interest; (ii) one or two stem loop caps; and (iii) one or more peptides linked to one of the stem loop caps or both of the stem loop caps. Optimization parameters of the peptide-modified gene cassettes disclosed herein include choice of peptide sequences (e.g., NLS peptides sequences); linker sequences and length; and single or dual peptide modification.
[0058] The exogenous nucleic acid encoding a gene of interest can encode any desired gene product, including proteins, peptides, regulatory RNAs, or gene-editing components (e.g., nucleases or guide RNAs when part of a broader system). The exogenous nucleic acid can include one or more of: an open reading frame (ORF); one or more promoters; one or more enhancers; a poly-A tail and / or polyadenylation signal region; and one or more flanking restriction sites. Promoters and enhancers may be selected to provide constitutive, inducible, tissue-specific, or otherwise regulated expression. In some embodiments, the gene cassette includes additional features such as untranslated regions (UTRs), introns, insulators, operator sequences, transcriptional terminators, stabilizing elements, or selection markers. The nucleic acid encoding a gene of interest can encode cytosolic or a secreted protein. The gene cassette of the nucleic acid encoding a gene of interest can exogenous nucleic acid encoding a gene of interest can range in size from 100 to 10,000, 200 to 9,000, 500 to 8,000, 1000 to 7000, 2,000 to 6,000, 3,000 to 6,000, or 4,000 to 5,000 base pairs in length. These elements may be included or omitted depending on the intended application and are not limiting.
[0059] The DNA-PepTAG workflow disclosed herein includes linking the exogenous nucleic acid encoding a gene of interest to one or two stem loop caps to produce a capped linear gene cassette, i.e., the peptide-modified gene cassettes of the present disclosure. The stem loop can include a region of nucleic acid that forms an intramolecular duplex (stem) and a non-duplex region (loop). In some embodiments, the stem loop includes a target guanine. In some embodiments, the stem loop is extended at either the 5' or 3' end or both to produce a sticky
[0060] end. For example, the 5' end can be extended to match a required restriction enzyme sticky end e.g.. Mlul). In some embodiments, E. coli TGT irreversibly exchanges a specific guanine of the stem loop with a preQi -DBCO in the DNA oligonucleotide stem loop to generate a DBCO modified DNA stem loop. In some embodiments, stem loops function asAttorney Docket No. 15670-0461W01
[0061] attachment sites for coupling peptides (e.g., NLS peptides) to the peptide-modified gene cassettes disclosed herein.
[0062] In some embodiments, the peptide-modified gene cassette comprises one or more peptide sequences, e.g., NLS peptides, operably linked to one or more stem loops. The peptide sequences (e.g., NLS peptides sequences) are coupled to the exogenous nucleic acid encoding a gene of interest via the linked stem loop. When the peptide sequence or sequences are NLS peptide sequences, upon contacting a cell with the peptide-modified gene cassette, the cassette is capable of translocating through a nuclear pore complex to deliver the exogenous nucleic acid encoding a gene of interest to the nucleus. When the peptide sequence or sequences are NLS peptide sequences, the one or more NLS peptide sequences can be selected from the group consisting of, for example: Sv40 (e.g., SV40 large T antigen NLS), extSv40, Influenza A Virus A NP, IGFBP-2, Hrp-1, PLSCR-1, Borna Disease Virus plO (BVP), and HTLV-1 Rex.
[0063] In some embodiments, peptide sequences (e.g., NLS peptides sequences) are used singly. In some embodiments, peptide sequences (e.g., NLS peptides sequences) are used in combinations. In some embodiments, multiple copies of the same peptide sequence are coupled to the nucleic acid, one copy to each stem loop cap. In other embodiments, different peptide sequences are coupled to provide multiplexed or synergistic properties, for example, nuclear import properties when the peptides sequences are NLS sequences.
[0064] The peptide-modified gene cassette can include one or more linkers (e.g., a (GGGGS)n linker) between the exogenous nucleic acid encoding a gene of interest and the peptide (e.g. the NLS peptide). When the peptide sequence or sequences are NLS peptide sequences, linkers can be selected to provide an appropriate spacing between the nucleic acid and the peptide to reduce steric hindrance, preserve NLS accessibility, and maintain nucleic acid integrity. In some embodiments, the linker comprises (GGGGS)i (SEQ ID NO: 1) to
[0065] provide a relatively short spacer. In other embodiments, the linker comprises (GGGGS)2
[0066] (SEQ ID NO: 2), (GGGGS)s (SEQ ID NO: 3), (GGGGS)4(SEQ ID NO: 4), or (GGGGS)s (SEQ ID NO: 5) to provide additional flexibility and spacing. Linker selection may be optimized to enhance NLS accessibility and nuclear import without compromising nucleic acid function. In some embodiments, the one or more linkers comprise peptide linkers selected from the group consisting of: (GGGGS)i, (GGGGS)2, (GGGGS)3, (GGGGS)4, and (GGGGS)s,Attorney Docket No. 15670-0461W01
[0067] In some embodiments, linkers may be substituted or augmented with additional spacer elements (e.g., polyethylene glycol units, alkyl spacers, or other flexible linkers), provided the resulting construct remains operably linked and supports nuclear delivery.
[0068] Nuclear Delivery of Exogenous Nucleic Acid
[0069] In some embodiments, a method of delivering an exogenous nucleic acid to a nucleus of a cell includes contacting the cell with the peptide-modified gene cassette as described herein. Contacting may be performed by any suitable approach, including any transfection method well known in the art, incubation of cells with the cassette in culture media, delivery in a formulated composition (e.g., buffered solution), or use of delivery aids (e.g., transfection reagents or physical delivery methods).
[0070] In some embodiments, contacting is performed under conditions that permit uptake of the peptide-modified gene cassette into the cell cytoplasm and subsequent nuclear trafficking. In some embodiments, contacting is performed in vitro, ex vivo, or in vivo.
[0071] In some embodiments, after the peptide-modified gene cassette enters a cell, the NLS peptide(s) facilitate association of the cassette with nuclear import machinery and / or nuclear pore components, enabling the cassette to translocate through a nuclear pore complex.
[0072] In some embodiments, the NLS peptide(s) promote active transport into the nucleus. In some embodiments, the peptide-modified gene cassette exhibits enhanced nuclear localization relative to a comparable nucleic acid lacking an operably linked NLS peptide.
[0073] The cells contacted according to the disclosed methods may include any suitable cell type, including mammalian cells, primary cells, stem cells, immune cells, or transformed cell lines. In some embodiments, the methods are performed on dividing or non-dividing cells, and the NLS peptide coupling may be particularly useful for improving nuclear delivery in contexts where passive nuclear entry is limited.
[0074] Methods of Making Peptide-Modified Gene Cassettes
[0075] An exemplary method of making the peptide-modified gene cassettes disclosed herein is presented below in Example 1. In some embodiments, a method of making a peptide-modified gene cassette comprises contacting a preQi -DBCO with a DNA oligonucleotide stem loop to generate a DBCO modified DNA stem loop.
[0076] In some embodiments, the DNA oligonucleotide stem loop is designed to adopt a stem -loop structure under suitable conditions (e.g., ionic strength and temperature). In some embodiments, the preQi-DBCO reagent provides a functional group that results inAttorney Docket No. 15670-0461W01
[0077] incorporation, installation, or presentation of a DBCO moiety on the DNA stem loop, thereby forming a DBCO-modified stem loop.
[0078] The contacting may be performed in solution under conditions effective to achieve the desired modification, including appropriate pH, salt concentrations, and reaction time.
[0079] In some embodiments, the method further comprises forming a triazole linkage between the DBCO modified DNA stem loop and an azido-peptide to generate a DNA oligonucl eoti de-pepti de conj ugate .
[0080] In some embodiments, the azido-peptide comprises an NLS peptide or comprises an NLS peptide operably linked to a linker. In some embodiments, the triazole linkage results from an azide-alkyne cycloaddition reaction between an azide group on the peptide and the DBCO moiety on the DNA stem loop, generating a stable covalent bond.
[0081] In some embodiments, the linker (e.g., (GGGGS)n) is positioned between the NLS sequence and the conjugation moiety, and the triazole linkage is formed at a terminus of the linker.
[0082] In some embodiments, the method comprises contacting the DNA oligonucleotidepeptide conjugate with a gene cassette to generate the peptide-modified gene cassette.
[0083] In some embodiments, contacting results in association of the DNA oligonucleotidepeptide conjugate with the gene cassette through base pairing, ligation, hybridization, recombination, or other assembly processes. In some embodiments, the DNA oligonucleotide portion of the conjugate is configured to anneal to a complementary region of the gene cassette, thereby positioning the NLS peptide relative to the gene cassette.
[0084] In some embodiments, the gene cassette comprises terminal sequences configured to accept one or more oligonucleotide conjugates, thereby enabling modular assembly of peptide-modified constructs, e.g., sticky end annealing.
[0085] In some embodiments, the method further comprises extending the 5' end of the DBCO modified DNA stem loop. In some embodiments, the method further comprises extending the 3' end of the DBCO modified DNA stem loop.
[0086] In some embodiments, the extending forms a sticky end at the 5' end and / or the 3' end of the DBCO modified DNA stem loop. Sticky ends may facilitate directional and / or efficient assembly to a gene cassette having complementary sticky ends.Attorney Docket No. 15670-0461W01
[0087] In some embodiments, the gene cassette is a sticky-ended gene cassette, and the DNA oligonucleotide-peptide conjugate is annealed and / or ligated to the gene cassette through complementary sticky ends to yield the peptide-modified gene cassette.
[0088] In some embodiments, the method further comprises contacting the gene cassette to a second DNA oligonucleotide-peptide conjugate. In some embodiments, multiple conjugates are attached to a single gene cassette at different positions and / or termini. The second conjugate may carry the same NLS peptide or a different NLS peptide, and may include the same linker length or a different linker length.
[0089] In some embodiments, attaching multiple conjugates increases the number of NLS peptides per gene cassette, which may increase nuclear import efficiency.
[0090] EXAMPLES
[0091] Materials and Methods
[0092] General Information
[0093] All reagents and buffers were obtained from Sigma-Aldrich unless otherwise specified. Oligonucleotides were synthesized by Integrated DNA Technologies. DBCO-NHS was purchased from BroadPharm, and preQl-biotin was provided by Tocris Bioscience.
[0094] Polyacrylamide gel electrophoresis (PAGE) was performed using 19:1 sequencinggrade urea PAGE gels (Sequagel system, National Diagnostics) in a Bio-Rad Mini-Protean system. Gels were stained with GelRed (Biotium) and imaged using a Bio-Rad ChemiDoc-MP gel imager. Image analysis was conducted using Fiji / ImageJ software (NIH).
[0095] Protein purification was carried out via fast protein liquid chromatography (FPLC) using a Cytiva AKTA Pure system. All natural Fmoc-protected amino acids were obtained from CEM, Chem-Impex Inf 1, ChemPep, Sigma-Aldrich, and TCI. Fmoc-L-Lys(N3)-OH was purchased from Sigma-Aldrich. Peptide synthesis was performed at a 0.1 mmol scale using a CEM Liberty Blue Microwave Peptide Synthesizer. Trityl-OH ChemMatrix resin (100-200 mesh, 0.37 mmol / g) from Biotage was used for microwave-assisted solid-phase peptide synthesis. All commercially sourced reagents were used without further purification unless otherwise noted.
[0096] Flow cytometry experiments for GFP expression were conducted on a Bio-Rad S3e Cell Sorter. Confocal microscopy was performed using a Zeiss Cell Observer® SD spinning disk system (Yokogawa, Japan) integrated into an Axio Observer Z1 motorized invertedAttorney Docket No. 15670-0461W01
[0097] microscope (Zeiss, Germany). Microscopy images were analyzed using Fiji / ImageJ software (NIH).
[0098] All bio-reagents, restriction enzymes, DNA purification kits, and competent bacterial strains were obtained from New England Biolabs, Life Technologies, or Promega.
[0099] Absorbance measurements were recorded using a Thermo Scientific NanoDrop 2000c UV-Vis spectrophotometer. High-resolution mass spectrometry (FIRMS) for small molecule probes, peptides, and modified oligonucleotides was performed using an Agilent 6230 time-of-flight mass spectrometer (TOF-MS) with a JetStream electrospray ionization (ESI) source at the UCSD Department of Chemistry and Biochemistry Molecular Mass Spectrometry Facility.
[0100] DNA Oligonucleotides and Plasmid Sequences
[0101] Oligonucleotide stem loops used in this work for DNA oligonucleotide-peptide conjugates and ligation to expression cassettes were ordered from Integrated DNA Technologies. DNA-TAG recognition stem loops are underlined; sticky end portion for ligation is bolded in Table 1 below. Stem loops were modified on the 5' position with a phosphate to facilitate ligation.
[0102] Table 1: Exemplary Oligonucleotide Stem Loops
[0103] Stem loop Sequence
[0104] Mlul 170 PP 5'-5 / Phos / CGCGCCGGATTGTCCTTCCGG-3'
[0105] (SEQ ID NO: 6)
[0106] Avril 170 PP 5'-5 / Phos / CTAGCCGGATTGTCCTTCCGG-3'
[0107] (SEQ ID NO: 7)
[0108] Afllll 170 PP 5'-5 / Phos / CGCGCCGGATTGTCCTTCCGG-3'
[0109] (SEQ ID NO: 8
[0110]
[0111] All peptide modified gene cassettes used for transfection experiments are driven by the same CMV enhanced and promoter and have the same bGH poly(A) signal found within the pcDNA3.1 plasmid vector to keep the expression of genes following mammalian transfection similar.Attorney Docket No. 15670-0461W01
[0112] TGT Expression and Purification
[0113] E. coli TGT was expressed as follows: a plasmid encoding TGT was transformed into BL21(DE3)pLysS chemically competent E. coli (Invitrogen C606010) and plated on LB agar containing kanamycin. Individual colonies were expanded in a 10 mL overnight culture, then transferred to 1 L of LB with kanamycin. Cells were grown to an optical density of 0.4 - 0.6, cooled at 4°C for 1 hour, and induced with 1 mM IPTG at 18°C overnight. Bacterial pellets were collected by centrifugation (6,000*g, 20 min, 4°C), resuspended in 10 mL lysis buffer (20 mM sodium phosphate, 500 mM NaCl, 20 mM imidazole, 400 pM PMSF, pH 7.7), and sonicated on ice (20 min total, 1 min on / off cycles, 50% duty cycle). The lysate was cleared by centrifugation (10,000*g, 30 min, 4°C).
[0114] TGT was purified using an AKTA pure FPLC system. Crude lysate was loaded onto a HisTrap FF crude column (Cytiva), washed with lysis buffer, and eluted with His elution buffer (20 mM sodium phosphate, 500 mM NaCl, 500 mM imidazole, 400 pM PMSF, pH 7.7). The eluate was further purified by size-exclusion chromatography (SEC) on a Superdex 75 10 / 300 GL column using TGT storage buffer (25 mM HEPES, 150 mM NaCl, 1 mM EDTA). Enzyme concentrations were determined by A280 absorbance, and aliquots were stored at -80°C.
[0115] PreQi Probe Synthesis
[0116] PreQi-DBCO was synthesized as follows: a tert-butyloxycarbonyl (boc) protecting group from a preQi derivative was removed and the free amine was conjugated to NHS-DBCO from BroadPharm. The boc protected starting material was deprotected in 1 : 1 TFA / DCM for one hour. TFA was neutralized three times by washing with 10% TEA in DCM, roto-evaporating the solution between each wash. The resulting crude oil was dissolved in dry DMF and TEA was added dropwise. NHS-DBCO was dissolved in dry DMF and added to preQi-C6-NH2 in DMF dropwise with stirring. The reaction proceeded for two hours at room temperature. Then, DMF was evaporated, and the crude product was purified by HPLC. The final product was confirmed by HRMS (expected mass = 593.3114, measured mass = 594.3184 for H+ ion). Synthesis of preQi-DBCO is shown in FIG. 6.Attorney Docket No. 15670-0461W01
[0117] TGT Labeling
[0118] TGT -mediated DNA modification was performed as previously described. Reactions were conducted at 37°C for 4 hours in a thermocycler with a heated lid using the following conditions: 10 pM TGT, 2.5 pM DNA oligonucleotide, 20 pM preQi -X (preQi -biotin or DBCO), and lx TGT reaction buffer. Reaction components were mixed, vortexed gently, spun down, and incubated. Samples were analyzed directly via PAGE without purification, which did not impact gel shift resolution. Gels were analyzed using ImageJ software to determine percent yield by band intensity.
[0119] Urea PAGE Analysis
[0120] Urea PAGE was used to assess TGT activity on DNA substrates. Gels were prepared using the SequaGel UreaGel System (National Diagnostics EC-833) and run in a Mini-PROTEAN Tetra Vertical Electrophoresis Cell (Bio-Rad). Fresh gels (10 mL) were polymerized with 14 pL TEMED and 80 pL 10% ammonium persulfate. Samples (150-200 ng DNA oligonucleotide) were diluted in 2x RNA loading dye (NEB B0363S), denatured at 98°C for 5 min, and loaded into the gel. Electrophoresis was performed at 210V for 90 min in 1 x TBE buffer. Gels were stained with GelRed (1 : 1000 in TBE) for 5 min and imaged using a Bio-Rad ChemiDoc system.
[0121] Peptide Synthesis
[0122] Trityl chloride ChemMatrix resin was freshly prepared from trityl-OH ChemMatrix resin (270 mg, 0.1 mmol, 0.37 mmol / g loading). The resin was swelled in DCM / toluene (1:1, 5 mL) for 10 min, treated with AcCl (0.2 mL), and shaken overnight. The resin was washed with DCM (3x10 mL) before coupling with Fmoc-L-Lys(N3)-OH (80 mg, 0.2 mmol) in DCM containing DIEA (140 pL, 0.8 mmol) for 2 hours. Capping was performed using DCM:MeOH:DIEA (8.5: 1:0.5, 5 mL). Resin loading was quantified by Fmoc deprotection and absorbance measurement at 301 nm.
[0123] Peptides were synthesized at a 0.1 mmol scale using a CEM Liberty Blue microwave synthesizer with Fmoc-L-Lys(N3)-ChemMatrix resin. Deprotection was performed with 20% 4-methylpiperidine in DMF. Coupling reactions utilized a 5-fold excess of Fmoc-AA-OH, 0.5 M DIC in DMF, and 1.0 M Oxyma Pure (0.1 M DIEA in DMF). Following synthesis, peptides were cleaved using a TFA:TIS:H2O:DODT (92.5:2.5:2.5:2.5) cocktail for 3 hours. The filtrate was evaporated under argon, and peptides were precipitated in cold Et2O, centrifuged (7,000 rpm, 5 min), washed with Et2O, and dried under vacuum.Attorney Docket No. 15670-0461W01
[0124] Purification was performed via HPLC using a Zorbax SB-C18 semipreparative column with Phase A (H2O + 0.1% TFA) and Phase B (CH3CN + 0.1% TFA) gradients. Analytical HPLC was conducted on an Eclipse Plus C8 column with Phase A (H2O + 0.1% formic acid) and Phase B (CH3CN + 0.1% formic acid).
[0125] Copper-Free Click Reactions (SPAAC) for DNA oligonucleotide-peptide Conjugation DBCO-modified DNA oligonucleotides were conjugated to azido-peptides via strain-promoted azide-alkyne click (SPAAC) chemistry. SPAAC enables efficient triazole linkage formation between a strained cyclooctyne (DBCO) and an azide with near-quantitative yields under simple aqueous conditions. Following the TGT labeling reaction to modify DNA oligonucleotides with DBCO, azido-peptides were added directly to the reaction tube at a final concentration of 100 pM (5:1 azide to DBCO). The reaction was incubated at 37°C overnight with gentle shaking. DNA oligonucleotide-peptide conjugates were analyzed via UREA-PAGE and purified using the Oligo Clean & Concentrator kit (Zymo Research, D4061), eluting in pure water for subsequent ligation to the gene cassette.
[0126] Generation of NLS-Modified Gene Cassettes
[0127] The coding sequence of pcDNA 3.1 (+) eGFP was PCR-amplified using NEB Q5 High-Fidelity DNA Polymerase (NEB, M0494L). PCR products were purified with the Monarch Spin PCR & DNA Cleanup Kit (NEB, T1130L), eluted in pure water, and sequence-verified by Plasmidsaurus. To generate sticky-end gene cassettes, the PCR product underwent dual restriction digestion with MluI-HF (NEB, R3198L) and Avril (NEB, R0174L) for 1 hour at 37°C. Digested DNA was purified using the Monarch Spin kit by NEB.
[0128] Sticky-end DNA fragments were ligated to corresponding DNA oligonucleotides (5:1 oligonucleotide to DNA) overnight at 16°C using T4 DNA ligase (NEB, M0202L). The ligated DNA oligonucleotides were optionally modified with peptides as described earlier. Purified ligated linear DNA underwent T7 exonuclease (NEB, M0263S) treatment for 30 minutes at 37°C to remove unligated DNA. Successful ligation was confirmed via agarose gel electrophoresis and sequencing by Eton Biosciences. The same approach was used to generate NLS modified miniGFPl and factor IX gene cassettes. For ABE8e-P2A-eGFP gene cassettes, a similar strategy was applied using AfHII (NEB, R0541S) instead of Avril, with an AfHII sticky-end DNA oligonucleotide for ligation.Attorney Docket No. 15670-0461W01
[0129] Cell Culture
[0130] HepG2 (HB-8056, ATCC), HEK293T (CRL-3216, ATCC), and AC16 (CRL-3568, ATCC) cells were cultured per ATCC guidelines. HepG2 and HEK293T cells were maintained at 37°C with 5% CO2 in complete growth medium containing Dulbecco’s modified Eagle medium (DMEM, Gibco 11995065), 10% FBS, and 1% penicillin / streptomycin (Gibco 15070063). AC16 cells were cultured under similar conditions in DMEM / F12 (Thermo Fisher 11320-033) supplemented with 12.5% FBS and 1% penicillin / streptomycin.
[0131] For experiments, cells were seeded at -50% confluency in collagen-coated 96-well plates and incubated for 48 hours. Cells were then washed with PBS (pH 7.4) and cultured in complete medium supplemented with 0.75 pM aphidicolin (Thermo Fisher J60236.MCR) to induce growth arrest in S-phase. Cells remained in aphidicolin-containing media for 48 hours, after which growth arrest was confirmed using a Click-iT EdU Proliferation Assay (Invitrogen Cl 0499). Growth-arrested cells were subsequently transfected with eGFP or factor IX DNA constructs.
[0132] Flow Cytometry for eGFP Expression Quantification
[0133] HepG2, HEK293T, and AC16 cells were seeded in 96-well plates and transfected following 48 hours of growth arrest. DNA mixtures were diluted in Opti-MEM reduced-serum medium (Gibco, 31985062) to a final volume of 5 pL and combined with 0.3 pL of Lipofectamine 3000 (Invitrogen, L3000008) diluted to 5 pL in Opti-MEM, following manufacturer instructions. Notably, the P3000 reagent was excluded to prevent interference from NLS-containing lipid cations that could impact nuclear translocation observations. Unless otherwise specified (e.g., for DNA titration experiments in Figure 5a), 100 ng of plasmid, linearized gene cassette, or peptide-modified gene cassette was delivered per well. After 48 hours, cells were washed with 100 pL PBS and detached with 50 pL (20 pL for HEK293T cells) of Accumax (STEMCELL Technologies) for 5 minutes at 37°C. Cells were then resuspended in 100 pL of cold sort buffer (1 mM EDTA, 2% FBS in PBS), passed through a 35 pm cell strainer, and maintained on ice. Samples were analyzed using an S3e Cell Sorter (BioRad) to quantify eGFP-expressing cells.
[0134] Importazole Assay for Importin-f Inhibition
[0135] To determine optimal importazole (SML0341, Sigma-Aldrich) concentrations for importin-P inhibition, growth-arrested HepG2 cells were transfected with a NLS-eGFPAttorney Docket No. 15670-0461W01
[0136] plasmid and treated with increasing concentrations of importazole (0 - 25 pM) based on prior studies. After 24 hours, eGFP localization was monitored by fluorescence imaging to assess cytosolic retention, indicative of importin-P inhibition. A concentration of 10 pM was identified as optimal, effectively inhibiting importin-P while maintaining cell viability.
[0137] Growth-arrested HepG2 cells were then treated with 10 pM importazole, transfected with eGFP constructs, and analyzed for eGFP expression by flow cytometry after 24 hours.
[0138] Factor IX ELISA
[0139] HepG2 cells were seeded in 96-well plates and transfected following 48 hours of growth arrest. DNA mixtures were prepared as described earlier, using 100 ng of factor IX plasmid, linearized gene cassette, or peptide-modified gene cassette per well. After 48 hours, secreted factor IX levels were measured using an ELISA kit (ELH-F9, RayBiotech) according to the manufacturer's instructions. For the 48-hour expression study, 100 |J L of media was collected from each well for factor IX quantification. In the time-course study, 100 pL of media was collected at each time point and replaced with 100 pL of fresh growth arrest media until the next collection point.
[0140] Statistics and reproducibility
[0141] Statistical analysis was done using GraphPad Prism 10. All relevant information on statistical analysis, including p-values, the number of samples that were analyzed and the statistical test used can be found in the respective figure legends. Specific p-value comparisons are shown in the figures. No statistical method was used to predetermine sample size. No data were excluded from the analyses and experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment.
[0142] EXAMPLE 1: Peptide Conjugation to DNA Using DNA-PepTAG
[0143] A workflow for generating DNA oligonucleotide-peptide conjugates using DNA-TAG technology is shown in FIG. 2A. The modular nature of the platform allows functionalization of a custom DNA oligonucleotide sequence with a preQi-DBCO, a strained cyclooctyne that can be used for click chemistry, as long as the minimal TGT recognizable stem loop is present (FIG. 2A). Once covalently modified with a DBCO moiety, azide-containing peptides can be “clicked” to the functionalized DNA oligonucleotide. DNAAttorney Docket No. 15670-0461W01
[0144] oligonucleotide-peptide conjugates can then be ligated to linear DNA to generate peptide modified gene cassettes.
[0145] A preQi-DBCO probe was synthesized, purified, and characterized. The preQi-DBCO probe was incubated with TGT and a DNA oligonucleotide stem loop substrate and analyzed for TGT -mediated DNA modification via polyacrylamide gel electrophoresis (PAGE). An upward gel shift of the product was observed relative to the starting material as the mass of the DNA stem loop increased due to the exchange of guanine for the preQi probe (FIG. 2B, FIG. 8). TGT -mediated modification of the DNA stem loop with a DBCO proceeded with 92% efficiency. Compared to simple alkynes, DBCO allows for simplified reactions conditions, primarily the lack of a Cu(I) catalyst required for alkyne-azide click chemistry. Leveraging strain-promoted azide-alkyne cycloaddition (SPAAC) between DBCO modified DNA and synthesized azido-peptides allows for an orthogonal, non-reversible click reaction in water forming a triazole linkage.
[0146] Following the DBCO modification of a DNA stem loop by TGT, addition of azidopeptides to the reaction mixture results in the generation of DNA oligonucleotide-peptide conjugates with near quantitative yields (90-95%) after overnight incubation at 37°C (FIG.
[0147] 2D, FIG. 8). A schematic showing exemplary generation of the DNA oligonucleotide-peptide conjugates is shown in FIG. 7. Due to the high-yield generation of DNA oligonucleotide-peptide conjugates, purification was performed by using a standard DNA oligonucleotide cleaning column (Zymo Research). Application of DNA-TAG allows for a low cost and efficient methodology to modify DNA with a DBCO at near quantitative yields.
[0148] Traditional methods for incorporating click handles into DNA often require the introduction of unnatural nucleobases during solid-phase phosphoramidite synthesis, leading to increased costs, extensive purification steps, and, in some cases, additional chemical modifications. In contrast, the methods disclosed herein uniquely enable site-specific, internal labeling of pre-synthesized, commercially available DNA oligonucleotides with a strained cyclooctyne. These methods streamline the generation of internally modified DBCO-labeled DNA oligonucleotides. By leveraging a post-synthetic conjugation strategy, the methods disclosed herein provide a modular and efficient platform for click conjugation of azidopeptides to generate DNA oligonucleotide-peptide conjugates.
[0149] A capped linear gene cassette that can be modified with peptides was utilized (FIG.
[0150] 2D). A plasmid containing an eGFP gene cassette flanked by two unique restriction sites, Avril and Mlul, was selected. The eGFP gene cassette was PCR amplified and digested to generate a linear eGFP fragment with defined sticky ends. TGT recognizable DNAAttorney Docket No. 15670-0461W01
[0151] oligonucleotide stem loops were designed such that they can be ligated to the to the sticky end eGFP fragment generating a capped eGFP gene cassette. Either or both DNA oligonucleotide stem loops (A and / or B) can be modified with azido-peptides, effectively generating a precise single or dual peptide modified eGFP gene cassettes. NLS modified gene cassettes can be rapidly generated by DNA-PepTAG, providing a versatile platform for studying peptide-mediated intracellular delivery of DNA cargo.
[0152] EXAMPLE 2: Optimization of NLS Modified Gene Cassettes for Gene Expression in Growth Arrested Cells
[0153] The 5' Mlul sticky end of the NLS modified gene cassette was ligated with a DNA oligonucleotide stem loop modified with different NLS peptides and transfected into aphidicolin growth arrested HepG2 cells (FIGs. 3A and 3B). HepG2 cells are a well-characterized human hepatocellular carcinoma cell line widely used in drug delivery and gene therapy studies due to their metabolic activity and relevance to liver-targeted therapeutics. By growth arresting HepG2 cells, we can better assess the impact of NLS modifications on DNA nuclear translocation and subsequent expression. Greater expression of eGFP was observed from DNA constructs modified with NLS peptides (FIG. 3B). The presence of a peptide did not have observable increases to eGFP expression as is the case of the Sv40 KO peptide modification compared to the linear control (FIG. 3B).
[0154] Before screening a number of NLS peptides for their ability to increase nuclear translocation and expression of DNA cargo, the eGFP expression cassette was optimized. In particular, the peptide linker length between the NLS and DNA cargo, as well as the number of NLS modifications, and the resulting affect on the efficiency of DNA nuclear translocation was evaluated (FIG. 3 A). The fraction of cells fluorescing, quantified by flow cytometry, was used as a proxy for the number of cells with nuclear translocated DNA.
[0155] 5' Sv40 NLS modified eGFP expression cassettes were generated with varying lengths of the flexible (GGGGS)nlinker sequence between the NLS portion of the peptide and the lysine containing azide and these constructs were transfected into growth arrested HepG2 cells for expression (FIGs. 3C and 4A, Table 2). Increasing the linker length from lx to 3x significantly (p < 0.001) enhanced eGFP expression, indicating that charge separation and greater peptide-DNA spacing improve NLS-DNA nuclear translocation. However, when the linker length was increased further to 4x and 5x, no increase (p > 0.05) in eGFPAttomey Docket No. 15670-0461W01
[0156] expression was observed. Further, linker length with a less positively charged Influenza-derived NLS was evaluating, resulting in only moderate eGFP increases (FIG. 9). These results indicated the role of charge separation in DNA-NLS nuclear translocation.
[0157] Table 2: Peptides Synthesized with a C terminal Azido-Modified Lysine and Flexible GGGGS Linkers
[0158] Peptide mw Sequence (N->C)
[0159] Sv40 NLS Lx1 1944.16 PKKKRKVEDPYS(GGGGS)IK(N3) (SEQ ID NO: 9) Sv40 NLS Lx2 2259.45 PKKKRKVEDPYS(GGGGS)2K(N3) (SEQ ID NO: 10) Sv40 NLS Lx3 2574.73 PKKKRKVEDPYS(GGGGS)3K(N3) (SEQ ID NO: 11) Sv40 NLS Lx4 2872.02 PKKKRKVEDPYS(GGGGS)4K(N3) (SEQ ID NO: 12) Sv40 NLS Lx5 3205.30 PKKKRKVEDPYS(GGGGS)5K(N3) (SEQ ID NO: 13) Influenza A Virus A 2976.10 MASQGTKRSSYEQMETDGERQS(GGGGS)IK(N3) (SEQ NP NLS Lx1 ID NO: 14)
[0160] Influenza A Virus A 3291.39 MASQGTKRSSYEQMETDGERQS(GGGGS)2K(N3) (SEQ NP NLS Lx2 ID NO: 15)
[0161] Influenza A Virus A 3606.68 MASQGTKRSSYEQMETDGERQS(GGGGS)3K(N3) (SEQ NP NLS Lx3 ID NO: 16)
[0162] Sv40 KO Lx3 2547.66 PKTKRKVEDPYS(GGGGS)3K(N3) (SEQ ID NO: 17) exSv40 NLS Lx3 4031.13 SSDEEATADQHSTPPKKKRKVEDPYS(GGGGS)3K(N3)
[0163] (SEQ ID NO: 18)
[0164] Borna disease virus 2936.21 LRLTLLELVRRLNGNG(GGGGS)3K(N3) (SEQ ID NO: 19) p10 (BVP) NLS Lx3
[0165] HTLV-1 NLS Lx3 3404.77 MPKTRRRPRRSQRKRPPT(GGGGS)3K(N3) (SEQ ID NO: 20)
[0166] IGFBP2 NLS Lx3 3203.51 KHHLGLEEPKKLRPPPAR(GGGGS)3K(N3) (SEQ ID NO:
[0167] 21)
[0168] Hrp-1 NLS Lx3 4186.27 RSGGNHRRNGRGGRGGYNRRNNGYHPY(GGGGS)3K(
[0169] N3) (SEQ ID NO: 22)
[0170]
[0171] PLSCR-1 NLS Lx3 2226.34 GKISKHWTGI(GGGGS)3K(N3) (SEQ ID NO: 23)
[0172] The methods disclosed herein, DNA-PepTAG, enable straightforward and precise NLS modification of DNA gene cassettes at either the 5' or 3' end (FIGs. 2D and 3A). eGFP
[0173] cassettes modified at either the 5' Mlul or, 3' Avril sticky ends or, alternatively, modified at both sites with Sv40 or Influenza-derived NLS peptides (FIG. 3D) were tested. While single-Attorney Docket No. 15670-0461W01
[0174] end modifications had similar (p > 0.05) eGFP expression, dual-end modification drastically reduced expression (<1%).
[0175] To assess whether NLS-modified DNA interacts with nuclear import factors, we transfected importazole-treated HepG2 cells (FIG. 3E). Importazole, an importin-P inhibitor, reduced eGFP expression of NLS modified expression cassettes to control levels, indicating NLS-mediated DNA translocation via importin-p.
[0176] EXAMPLE 3: Screening NLS Peptides for Enhanced Gene Expression
[0177] A single 5' Mlul modified NLS with a (GGGGSf (SEQ ID NO: 3) linker was used for screening alternative NLS peptides for nuclear translocation efficiency. A diverse set of NLS peptides was screened for modification of the eGFP cassette to assess their ability to enhance eGFP expression in growth arrested human cells, serving as a marker for nuclear translocation. A variety of NLS peptides were chosen based on amino acid composition, polarity / charge state, length, mechanism of proposed nuclear translocation, and origin of NLS (FIG. 4A, Table 2). Further, a control Sv40 KO NLS peptide with a K- T mutation was synthesized and conjugated to the eGFP cassette. Additional controls included a capped, peptide-free linear gene cassette, and the eGFP plasmid. All eGFP constructs were transfected into three growth arrested human cell lines; HepG2, derived from hepatic cells, HEK293T, human embryonic kidney cells, and AC16s, derived from primary ventricular tissue, and monitored for eGFP expression by flow cytometry (FIG. 4B).
[0178] Active NLS modifications of the eGFP gene cassette resulted in greater expression of eGFP compared to the controls, indicating that the presence of an NLS on a DNA cargo does improve its nuclear delivery in all cell types. The presence of a peptide on the DNA cargo does not appear to increase expression as the Sv40 KO peptide had low, comparable expression to the other controls. The degree to which eGFP expression was increased by NLS modification was variable between cell type and peptide. For example, while PLSCR-1 and exSv40 NLS modifications consistently had high expression across all three cell types, the other NLS modifications were more variable in their degree of expression enhancement depending on cell type. PLSCR-1 may bind importin-a more efficiently when conjugated to a DNA cargo due to its short, relatively nonpolar nature, which minimizes electrostatic interactions with DNA. Expression differences across cell types may stem from variations in endogenous nuclear transport factors, particularly importin-a isoforms.Attorney Docket No. 15670-0461W01
[0179] These results indicate that specific NLS peptides can be preferred for DNA nuclear translocation, as IGFBP2-1 and Hrp-1 NLS modifications show lower expression in hepatic-derived HepG2 cells but significantly enhance eGFP expression in kidney-derived HEK293T and cardiomyocyte AC 16 cells. The results also indicate potential for designing NLS peptides tailored for selective DNA cargo expression in specific tissues.
[0180] EXAMPLE 4: Therapeutic Considerations of NLS Modified Genes
[0181] Growth-arrested HepG2 cells were transfected with decreasing amounts of eGFP expressing DNA (FIG. 5A). Based on prior screening (FIG. 4B), PLSCR-1 and exSv40 NLS peptide modifications were selected, as they most effectively enhanced gene expression in HepG2 cells. Reducing the transfected DNA amount (100 ng to 1 ng per well) decreased overall eGFP expression. However, NLS-modified DNA constructs exhibited significantly higher eGFP expression (p < 0.001) than all controls at every DNA concentration. At 10 ng
[0182] transfections, NLS-modified gene cassettes achieved -5-6% eGFP expression, surpassing eGFP expression of the controls at 100 ng transfections. These findings indicate that DNA-NLS conjugates can enhance gene delivery efficiency at low doses, suggesting potential for therapeutic applications, as minimizing the required DNA dose can advantageously reduce cytotoxicity and immune activation.
[0183] Differently sized DNA cargos were evaluated for NLS modification. In addition to the original eGFP gene cassette (2537 bp), linear expression cassettes were generated for miniGFPl (1361 bp) and ABE8e-P2A-eGFP (6976 bp), amenable to peptide modification. Growth-arrested HepG2 cells were transfected with NLS-modified miniGFPl, eGFP, and ABE8e-P2A-eGFP gene cassettes and GFP expression was evaluated (FIG. 5B). All three DNA cargos were similar in that NLS peptide modified constructs had significantly (p < 0.001) enhanced expression over controls (FIG. 5B). Expression levels were comparable between miniGFPl and eGFP, while ABE8e-P2A-eGFP exhibited lower expression. These results indicate that NLS modified gene cassettes can accommodate cargos up to -7000 bp while maintaining enhanced nuclear delivery.
[0184] The potential of NLS modified gene cassettes to express a clinically relevant gene, coagulation factor IX, was assessed. Factor IX is a serine protease essential for blood coagulation, and mutations in its gene cause hemophilia B (Christmas disease). Current treatment relies on recombinant factor IX administration.Attorney Docket No. 15670-0461W01
[0185] A human factor IX gene cassette compatible with NLS peptide modifications was designed and transfected into growth-arrested HepG2 cells, and factor IX secretion was measured via ELISA (FIG. 5C). NLS-modified factor IX cassettes exhibited significantly higher secretion (p < 0.001) than controls, mirroring the enhancement seen in eGFP expression (FIG. 4B). The same NLS peptides that enhanced eGFP expression in HepG2 cells also increased factor IX secretion, following identical trends across both gene cassettes within the same cell type. These results indicate that specific NLS peptides can facilitate nuclear translocation in a cell- or tissue-dependent manner, regardless of the gene being delivered.
[0186] Using the most effective NLS modifications, factor IX secretion was monitored over 120 hours (FIG. 5D). From 48 hours onward, NLS modified constructs maintained significantly higher secretion levels with ~10-fold increases observed compared to controls. Since media was replaced at each time point without additional DNA delivery, expression beyond 24 hours indicates sustained transcription from the initial transfection. These results indicate that NLS modified gene cassettes can enhance the expression of therapeutically relevant proteins, and can be used for, e.g., recombinant protein production and non-viral gene therapy applications.
Claims
Attorney Docket No. 15670-0461W01WHAT IS CLAIMED IS:
1. A method of delivering an exogenous nucleic acid to a nucleus of a cell, the method comprising:contacting the cell with a peptide-modified gene cassette, the peptide-modified gene cassette comprising:(i) an exogenous nucleic acid molecule;(ii) one or more linkers; and(iii) one or more nuclear localization (NLS) peptides;such that the peptide-modified gene cassette translocates through a nuclear pore complex of the nucleus of the cell, thereby delivering the exogenous nucleic acid to the nucleus of the cell.
2. The method of claim 1, wherein the exogenous nucleic acid molecule comprises a DNA molecule.
3. The method of claim 2, wherein the DNA molecule comprises a gene of interest.
4. The method of claim 3, wherein the gene of interest comprises an open reading frame (ORF), one or more enhancers, one or more promoters, a poly-A tail, and one or more flanking restriction sites.
5. The method of any one of claims 1-4, wherein the peptide-modified gene cassette further comprises one or more stem loops.
6. The method of any one of claims 1-5, wherein the one or more NLS peptides are operably linked to the one or more stem loops.
7. The method of any one of claims 1-6, wherein the one or more NLS peptides are selected from the group consisting of Sv40, exSv40, Influenza A Virus A NP, IGFBP-2, Hrp-1, PLSCR-1, Borna Disease Virus plO (BVP), and HTLV-1 Rex.
8. The method of any one of claims 1-7, wherein the peptide-modified gene cassette further comprises a triazole linkage.Attorney Docket No. 15670-0461W019. The method of claim 8, wherein the triazole linkage links the one or more stem loops to the one more linkers.
10. A composition comprising a peptide-modified gene cassette, the peptide-modified gene cassette comprising:(i) an exogenous nucleic acid molecule;(ii) one or more linkers; and(iii) one or more nuclear localization (NLS) peptides.
11. The composition of claim 10, wherein the exogenous nucleic acid molecule is a DNA molecule.
12. The composition of claim 11, wherein the DNA molecule comprises a gene of interest.
13. The composition of claim 12, wherein the gene of interest comprises an open reading frame (ORF), one or more enhancers, one or more promoters, a poly-A tail, and one or more flanking restriction sites.
14. The composition of any one of claims 10-13, wherein the peptide-modified gene cassette further comprises one or more stem loops.
15. The composition of any one of claims 10-14, wherein the one or more NLS peptides are operably linked to the one or more stem loops.
16. The composition of any one of claims 10-15, wherein the one or more NLS peptides are selected from the group consisting of Sv40, exSv40, Influenza A Virus A NP, IGFBP-2, Hrp-1, PLSCR-1, Borna Disease Virus plO (BVP), and HTLV-1 Rex.
17. The composition of any one of claims 10-16, wherein the peptide-modified gene cassette further comprises a triazole linkage.Attorney Docket No. 15670-0461W0118. The composition of claim 17, wherein the triazole linkage links the one or more stem loops to the one more linkers.
19. A method of making a peptide-modified gene cassette, the method comprising:contacting a preQi -DBCO with a DNA oligonucleotide stem loop to generate a DBCO modified DNA stem loop;forming a triazole linkage between the DBCO modified DNA step loop and an azidopeptide to generate a DNA oligonucleotide-peptide conjugate;contacting the DNA oligonucleotide-peptide conjugate with a gene cassette to generate a peptide-modified gene cassette.
20. The method of claim 19, further comprising contacting the gene cassette to a second DNA oligonucleotide-peptide conjugate.
